Skip to main content

Table 2 Lipid profile during the study period by treatment group, repeated measures and Bonferroni post hoc analysis, using last observation carried forward method for missing data

From: Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?

  

PJ

Placebo

P***for PJ vs. placebo at 12 m

  

N

Mean ± SD

P for trend

N

Mean ± SD

P for trend

LDL mg/dl

0

66

95.1 ± 31.5

0.07

35

95.8 ± 28.9

0.38

0.85

3 M

98.9 ± 35.6

98.0 ± 28.1

 

6 M

95.4 ± 32.4

91.8 ± 25.1

12 M

100.0 ± 33.1

94.3 ± 27.2

0.39

Total cholesterol mg/dl

0

66

164.8 ± 37.1

0.27

35

163.5 ± 33.4

0.18

0.86

3 M

167.7 ± 40.7

171.7 ± 35.1

 

6 M

163.4 ± 38.9

164.8 ± 38.0

12 M

167.3 ± 43.5

165.1 ± 35.8

0.79

HDL mg/dl

0

66

33.1 ± 9.5*

<0.001

35

36.6 ± 10.7

0.18

0.10

3 M

37.2 ± 11.3

37.0 ± 11.7

 

6 M

36.6 ± 10.9

37.3 ± 12.9

12 M

36.8 ± 10.8

34.3 ± 15.4

0.40

HDL ≤40 mg/dl at study initiation

0

54

29.7 ± 5.7*

<0.001

23

30.2 ± 5.6

0.09

0.84

3 M

33.8 ± 7.8

31.2 ± 7.6

 

6 M

33.6 ± 7.7

31.8 ± 10.2

12 M

33.6 ± 7.5

27.6 ± 11.6

0.03

TG mg/dl

0

66

183.6 ± 101.6**

0.05

35

176.7 ± 86.7

0.04

0.73

3 M

175.7 ± 90.8

192.9 ± 100.7

 

6 M

174.0 ± 89.8

193.6 ± 90.5

12 M

167.3 ± 86.3

206.1 ± 109.4

0.05

TG ≥200 mg/dl at study initiation

0

20

310.1 ± 87.8**

0.02

10

288.1 ± 71.9

0.15

0.13

3 M

267.3 ± 86.6

318.2 ± 96.6

 

6 M

248.7 ± 100.5

301.5 ± 78.2

12 M

237.4 ± 102.5

320.4 ± 56.8

0.008

  1. *P < 0.05 for zero time vs. 3, 6 and 12 m; **P < 0.05 for zero time vs. 6 m and 12 m; ***T-test or Mann-whitny U test.